Clostridium difficile infection in HIV-seropositive individuals and transplant recipients

Journal of Infection

Volumn 64, Issue 2, 2012, Pages 131-147

  Collini, Paul J ^a   Bauer, Martijn ^b   Kuijper, Ed ^b   Dockrell, David H ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clostridium difficile infection; HIV; HSCT; Immunocompromise; Transplant

Indexed keywords

AZATHIOPRINE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CYCLOSPORIN; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN DERIVATIVE; RIFAMPICIN; VANCOMYCIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIUM CULTURE; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; ENDOSCOPY; ENZYME IMMUNOASSAY; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY TRANSPLANTATION; LENGTH OF STAY; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; RECURRENT INFECTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

BONE MARROW TRANSPLANTATION; CLOSTRIDIUM DIFFICILE; COLITIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 84855883659     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.12.003     Document Type: Review

References (168)

1. Bauer M.P., Notermans D.W., van Benthem B.H., Brazier J.S., Wilcox M.H., Rupnik M., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377(9759):63-73.
2. Raines D.L., Lopez F.A. Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-Infected patients. Curr Gastroenterol Rep 2011, 13(4):344-350.
3. Morris A.M., Jobe B.A., Stoney M., Sheppard B.C., Deveney C.W., Deveney K.E. Clostridium difficile colitis: an increasingly aggressive iatrogenic disease?. Arch Surg 2002, 137(10):1096-1100.
4. Svenungsson B., Burman L.G., Jalakas-Pornull K., Lagergren A., Struwe J., Akerlund T. Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital. J Clin Microbiol 2003, 41(9):4031-4037.
5. Reddy S., Taori S., Poxton I.R. Changes in laboratory and clinical workload for Clostridium difficile infection from 2003 to 2007 in hospitals in Edinburgh. Clin Microbiol Infect 2010, 16(4):340-346.
6. Herrera P., Cotera A., Fica A., Galdo T., Alvo M. High incidence and complications of Clostridium difficile diarrhea among patients with renal diseases. Rev Med Chil 2003, 131(4):397-403.
7. Dallal R.M., Harbrecht B.G., Boujoukas A.J., Sirio C.A., Farkas L.M., Lee K.K., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002, 235(3):363-372.
8. Dudukgian H., Sie E., Gonzalez-Ruiz C., Etzioni D.A., Kaiser A.M. C. difficile colitis-predictors of fatal outcome. J Gastrointest Surg 2010, 14(2):315-322.
9. Gellad Z.F., Alexander B.D., Liu J.K., Griffith B.C., Meyer A.M., Johnson J.L., et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transpl Infect Dis 2007, 9(4):276-280.
10. Barbut F., Petit J.C. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001, 7(8):405-410.
11. McDonald L.C., Coignard B., Dubberke E., Song X., Horan T., Kutty P.K. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007, 28(2):140-145.
12. Bauer M.P., Kuijper E.J., van Dissel J.T. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15(12):1067-1079.
13. Deneve C., Janoir C., Poilane I., Fantinato C., Collignon A. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents 2009, 33(Suppl. 1):S24-S28.
14. Aslam S., Hamill R.J., Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005, 5(9):549-557.
15. Voth D.E., Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, 18(2):247-263.
16. Poxton I.R., McCoubrey J., Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect 2001, 7(8):421-427.
17. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7(7):526-536.
18. Ballard J.D. Medical microbiology: a toxin contest. Nature 2010, 467(7316):665-666.
19. Kim H., Rhee S.H., Kokkotou E., Na X., Savidge T., Moyer M.P., et al. Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J Biol Chem 2005, 280(22):21237-21245.
20. Warny M., Keates A.C., Keates S., Castagliuolo I., Zacks J.K., Aboudola S., et al. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest 2000, 105(8):1147-1156.
21. Savidge T.C., Urvil P., Oezguen N., Ali K., Choudhury A., Acharya V., et al. Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med 2011, 17(9):1136-1141.
22. Meyer G.K., Neetz A., Brandes G., Tsikas D., Butterfield J.H., Just I., et al. Clostridium difficile toxins A and B directly stimulate human mast cells. Infect Immun 2007, 75(8):3868-3876.
23. Vilhardt F., Plastre O., Sawada M., Suzuki K., Wiznerowicz M., Kiyokawa E., et al. The HIV-1 Nef protein and phagocyte NADPH oxidase activation. J Biol Chem 2002, 277(44):42136-42143.
24. Rezzani R. Exploring cyclosporine A-side effects and the protective role-played by antioxidants: the morphological and immunohistochemical studies. Histol Histopathol 2006, 21(3):301-316.
25. Dalmarco E.M., Budni P., Parisotto E.B., Wilhelm Filho D., Frode T.S. Antioxidant effects of mycophenolate mofetil in a murine pleurisy model. Transpl Immunol 2009, 22(1-2):12-17.
26. Varin A., Manna S.K., Quivy V., Decrion A.Z., Van Lint C., Herbein G., et al. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J Biol Chem 2003, 278(4):2219-2227.
27. Mangino G., Percario Z.A., Fiorucci G., Vaccari G., Manrique S., Romeo G., et al. In vitro treatment of human monocytes/macrophages with myristoylated recombinant Nef of human immunodeficiency virus type 1 leads to the activation of mitogen-activated protein kinases, IkappaB kinases, and interferon regulatory factor 3 and to the release of beta interferon. J Virol 2007, 81(6):2777-2791.
28. Menor C., Fernandez-Moreno M.D., Fueyo J.A., Escribano O., Olleros T., Arriaza E., et al. Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine. J Pharmacol Exp Ther 2004, 311(2):668-676.
29. Matsuda S., Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000, 47(2-3):119-125.
30. Shui H., Gao P., Si X., Ding G. Mycophenolic acid inhibits albumin-induced MCP-1 expression in renal tubular epithelial cells through the p38 MAPK pathway. Mol Biol Rep 2010, 37(4):1749-1754.
31. Andreucci M., Faga T., Lucisano G., Uccello F., Pisani A., Memoli B., et al. Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. Chem Biol Interact 2010, 185(3):253-262.
32. Goppelt-Struebe M., Wolter D., Resch K. Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase. Br J Pharmacol 1989, 98(4):1287-1295.
33. Martin M., Neumann D., Hoff T., Resch K., DeWitt D.L., Goppelt-Struebe M. Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 1994, 45(1):150-158.
34. Greenblatt M.B., Aliprantis A., Hu B., Glimcher L.H. Calcineurin regulates innate antifungal immunity in neutrophils. J Exp Med 2010, 207(5):923-931.
35. Jabs T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem Pharmacol 1999, 57(3):231-245.
36. Um H.D., Orenstein J.M., Wahl S.M. Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol 1996, 156(9):3469-3477.
37. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998, 58(2):362-366.
38. von Knethen A., Callsen D., Brune B. Superoxide attenuates macrophage apoptosis by NF-kappa B and AP-1 activation that promotes cyclooxygenase-2 expression. J Immunol 1999, 163(5):2858-2866.
39. Munoz P., Giannella M., Alcala L., Sarmiento E., Fernandez Yanez J., Palomo J., et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer?. J Heart Lung Transplant 2007, 26(9):907-914.
40. West M., Pirenne J., Chavers B., Gillingham K., Sutherland D.E., Dunn D.L., et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant 1999, 13(4):318-323.
41. Keven K., Basu A., Re L., Tan H., Marcos A., Fung J.J., et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis 2004, 6(1):10-14.
42. Sharma A.K., Holder F.E. Clostridium difficile diarrhea after use of tacrolimus following renal transplantation. Clin Infect Dis 1998, 27(6):1540-1541.
43. Manges A.R., Labbe A., Loo V.G., Atherton J.K., Behr M.A., Masson L., et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis 2010, 202(12):1877-1884.
44. Rea M.C., Dobson A., O'Sullivan O., Crispie F., Fouhy F., Cotter P.D., et al. Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 2011, 108(Suppl. 1):4639-4644.
45. Jia J.S., Huang X.J., Liu D.H., Xiu L.P., Zhang Y.C., Wu T., et al. Relationship between Clostridium difficile associated diarrhea and intestinal microecosystem disorder in patients received allogeneic hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008, 16(1):135-139.
46. Anand A., Glatt A.E. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993, 17(1):109-113.
47. Viscidi R., Laughon B.E., Yolken R., Bo-Linn P., Moench T., Ryder R.W., et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 1983, 148(1):93-100.
48. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000, 342(6):390-397.
49. Mulligan M.E., Miller S.D., McFarland L.V., Fung H.C., Kwok R.Y. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993, 16(Suppl. 4):S239-S244.
50. Johnson S., Gerding D.N., Janoff E.N. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 1992, 166(6):1287-1294.
51. Sanchez-Hurtado K., Corretge M., Mutlu E., McIlhagger R., Starr J.M., Poxton I.R. Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls. J Med Microbiol 2008, 57(Pt 6):717-724.
52. Gryboski J.D., Pellerano R., Young N., Edberg S. Positive role of Clostridium difficile infection in diarrhea in infants and children. Am J Gastroenterol 1991, 86(6):685-689.
53. Warny M., Vaerman J.P., Avesani V., Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994, 62(2):384-389.
54. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357(9251):189-193.
55. Aronsson B., Granstrom M., Mollby R., Nord C.E. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985, 13(3):97-101.
56. Leav B.A., Blair B., Leney M., Knauber M., Reilly C., Lowy I., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010, 28(4):965-969.
57. Knight A.K., Mayer L., Franks A.G., Cunningham-Rundles C. Hypogammaglobulinemia with facial edema. PLoS Med 2006, 3(12):e475.
58. Lowy I., Molrine D.C., Leav B.A., Blair B.M., Baxter R., Gerding D.N., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362(3):197-205.
59. Moir S., Malaspina A., Ogwaro K.M., Donoghue E.T., Hallahan C.W., Ehler L.A., et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A 2001, 98(18):10362-10367.
60. Conge A.M., Tarte K., Reynes J., Segondy M., Gerfaux J., Zembala M., et al. Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. AIDS 1998, 12(12):1437-1449.
61. Kuritzkes D.R. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 2000, 30(2):256-260.
62. Schalk E., Bohr U.R., Konig B., Scheinpflug K., Mohren M. Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol 2009.
63. Apostolopoulou E., Raftopoulos V., Terzis K., Elefsiniotis I. Infection probability score: a predictor of Clostridium difficile-associated disease onset in patients with haematological malignancy. Eur J Oncol Nurs 2010.
64. Tunccan O.G., Ulutan F., Karakus R. The frequency of Clostridium difficile toxin in neutropenic and non-neutropenic patients with antibiotic-associated diarrhea and analysis of the risk factors. Mikrobiyol Bul 2008, 42(4):573-583.
65. Toor A.A., van Burik J.A., Weisdorf D.J. Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplant 2001, 28(12):1129-1134.
66. Nomura K., Fujimoto Y., Yamashita M., Morimoto Y., Ohshiro M., Sato K., et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009, 44(1):74-78.
67. Kirkpatrick I.D., Greenberg H.M. Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. Radiology 2003, 226(3):668-674.
68. Kirkpatrick I.D., Greenberg H.M. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy?. AJR Am J Roentgenol 2001, 176(3):635-639.
69. Boland G.W., Lee M.J., Cats A.M., Gaa J.A., Saini S., Mueller P.R. Antibiotic-induced diarrhea: specificity of abdominal CT for the diagnosis of Clostridium difficile disease. Radiology 1994, 191(1):103-106.
70. Mahida Y.R., Galvin A., Makh S., Hyde S., Sanfilippo L., Borriello S.P., et al. Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis. Infect Immun 1998, 66(11):5462-5469.
71. Modi N., Gulati N., Solomon K., Monaghan T., Robins A., Sewell H.F., et al. Differential binding and internalisation of Clostridium difficile toxin A by human peripheral blood monocytes, neutrophils and lymphocytes. Scand J Immunol 2011.
72. Ryan A., Lynch M., Smith S.M., Amu S., Nel H.J., McCoy C.E., et al. A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog 2011, 7(6):e1002076.
73. Pulvirenti J.J., Gerding D.N., Nathan C., Hafiz I., Mehra T., Marsh D., et al. Difference in the incidence of Clostridium difficile among patients infected with human immunodeficiency virus admitted to a public hospital and a private hospital. Infect Control Hosp Epidemiol 2002, 23(11):641-647.
74. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366(9491):1079-1084.
75. Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 2008, 359(18):1932-1940.
76. Wanke C.A., Mayer H., Weber R., Zbinden R., Watson D.A., Acheson D. Enteroaggregative Escherichia coli as a potential cause of diarrheal disease in adults infected with human immunodeficiency virus. J Infect Dis 1998, 178(1):185-190.
77. Mathewson J.J., Salameh B.M., DuPont H.L., Jiang Z.D., Nelson A.C., Arduino R., et al. HEp-2 cell-adherent Escherichia coli and intestinal secretory immune response to human immunodeficiency virus (HIV) in outpatients with HIV-associated diarrhea. Clin Diagn Lab Immunol 1998, 5(1):87-90.
78. Gordon M.A., Kankwatira A.M., Mwafulirwa G., Walsh A.L., Hopkins M.J., Parry C.M., et al. Invasive non-typhoid salmonellae establish systemic intracellular infection in HIV-infected adults: an emerging disease pathogenesis. Clin Infect Dis 2010, 50(7):953-962.
79. Mwachari C., Batchelor B.I., Paul J., Waiyaki P.G., Gilks C.F. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. J Infect 1998, 37(1):48-53.
80. Larsen I.K., Gradel K.O., Helms M., Hornstrup M.K., Jurgens G., Mens H., et al. Non-typhoidal Salmonella and Campylobacter infections among HIV-positive patients in Denmark. Scand J Infect Dis 2011, 43(1):3-7.
81. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr 2002, 30(1):21-26.
82. Mastroianni A., Coronado O., Nanetti A., Valentini R., Manfredi R., Chiodo F. Nosocomial Clostridium difficile-associated diarrhea in patients with AIDS: a three-year survey and review. Clin Infect Dis 1997, 25(Suppl. 2):S204-S205.
83. Zulu I., Kelly P., Mwansa J., Veitch A., Farthing M.J. Contrasting incidence of Clostridium difficile and other enteropathogens in AIDS patients in London and Lusaka. Trans R Soc Trop Med Hyg 2000, 94(2):167-168.
84. Anastasi J.K., Capili B. HIV and diarrhea in the era of HAART: 1998 New York state hospitalizations. Am J Infect Control 2000, 28(3):262-266.
85. Sanchez T.H., Brooks J.T., Sullivan P.S., Juhasz M., Mintz E., Dworkin M.S., et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis 2005, 41(11):1621-1627.
86. Mainardi J.L., Lacassin F., Guilloy Y., Goldstein F.W., Leport C., Acar J.F., et al. Low rate of Clostridium difficile colonization in ambulatory and hospitalized HIV-infected patients in a hospital unit: a prospective survey. J Infect 1998, 37(2):108-111.
87. Pulvirenti J., Mehra T., Hafiz I., DeMarais P., Marsh D., Kocka F., et al. Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients. Diagn Microbiol Infect Dis 2002, 44(4):325-330. [Article].
88. Hutin Y., Casin I., Lesprit P., Welker Y., Decazes J.M., Lagrange P., et al. Prevalence of and risk factors for Clostridium difficile colonization at admission to an infectious diseases ward. Clin Infect Dis 1997, 24(5):920-924.
89. Barbut F., Meynard J.L., Guiguet M., Avesani V., Bochet M.V., Meyohas M.C., et al. Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16(3):176-181.
90. Hutin Y., Molina J.M., Casin I., Daix V., Sednaoui P., Welker Y., et al. Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients. AIDS 1993, 7(11):1441-1447.
91. Tumbarello M., Tacconelli E., Leone F., Cauda R., Ortona L. Clostridium difficile-associated diarrhoea in patients with human immunodeficiency virus infection: a case-control study. Eur J Gastroenterol Hepatol 1995, 7(3):259-263.
92. Bouza E., Padilla B., Catalan P., Sanchez-Carrillo C., Blazquez R., Pelaez T. Diarrhea associated with Clostridium difficile: one-year experience in a general hospital. Rev Clin Esp 1996, 196(7):424-430.
93. DeMarais P.L., Gertzen J., Weinstein R.A. Nosocomial infections in human immunodeficiency virus-infected patients in a long-term-care setting. Clin Infect Dis 1997, 25(5):1230-1232.
94. Mody L.R., Smith S.M., Dever L.L. Clostridium difficile-associated diarrhea in a VA medical center: clustering of cases, association with antibiotic usage, and impact on HIV-infected patients. Infect Control Hosp Epidemiol 2001, 22(1):42-45.
95. Buchner A.M., Sonnenberg A. Medical diagnoses and procedures associated with clostridium difficile colitis. Am J Gastroenterol 2001, 96(3):766-772.
96. Spencer R.C. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998, 41(Suppl. C):21-27.
97. Saddi V.R., Glatt A.E. Clostridium difficile-associated diarrhea in patients with HIV: a 4-year survey. J Acquir Immune Defic Syndr 2002, 31(5):542-543.
98. Samie A., Obi C.L., Franasiak J., Archbald-Pannone L., Bessong P.O., Alcantara-Warren C., et al. PCR detection of Clostridium difficile triose phosphate isomerase (tpi), toxin A (tcdA), toxin B (tcdB), binary toxin (cdtA, cdtB), and tcdC genes in Vhembe district, South Africa. Am J Trop Med Hyg 2008, 78(4):577-585.
99. Willingham F.F., Ticona Chavez E., Taylor D.N., Bowen A.B., Crane A.R., Gottlieb A.L., et al. Diarrhea and Clostridium difficile infection in Latin American patients with AIDS. Working group on AIDS in Peru. Clin Infect Dis 1998, 27(3):487-493.
100. Cappell M.S., Philogene C. Clostridium difficile infection is a treatable cause of diarrhea in patients with advanced human immunodeficiency virus infection: a study of seven consecutive patients admitted from 1986 to 1992 to a university teaching hospital. Am J Gastroenterol 1993, 88(6):891-897.
101. Lu S.S., Schwartz J.M., Simon D.M., Brandt L.J. Clostridium difficile-associated diarrhea in patients with HIV positivity and AIDS: a prospective controlled study. Am J Gastroenterol 1994, 89(8):1226-1229.
102. Zuckerman E., Kanel G., Ha C., Kahn J., Gottesman B.S., Korula J. Low albumin gradient ascites complicating severe pseudomembranous colitis. Gastroenterology 1997, 112(3):991-994.
103. Beaugerie L., Ngo Y., Goujard F., Gharakhanian S., Carbonnel F., Luboinski J., et al. Etiology and management of toxic megacolon in patients with human immunodeficiency virus infection. Gastroenterology 1994, 107(3):858-863.
104. Steinlauf A.F., Traube M., Neitlich J.D., Cooney E.L. Clostridium difficile colitis: a possible cause of unexplained elevation of serum alkaline phosphatase levels in patients with AIDS. Clin Infect Dis 1998, 26(5):1248-1249.
105. Crobach M.J., Dekkers O.M., Wilcox M.H., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009, 15(12):1053-1066.
106. Olofinlade O., Chiang C. Cytomegalovirus infection as a cause of pseudomembrane colitis: a report of four cases. J Clin Gastroenterol 2001, 32(1):82-84.
107. Younus F., Steigbigel R.T. Images in clinical medicine. Nodular Clostridium difficile colitis. N Engl J Med 2004, 350(10):e9.
108. Musher D.M., Aslam S., Logan N., Nallacheru S., Bhaila I., Borchert F., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005, 40(11):1586-1590.
109. Pepin J., Alary M.E., Valiquette L., Raiche E., Ruel J., Fulop K., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005, 40(11):1591-1597.
110. Kuijper E.J., Wilcox M.H. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?. Clin Infect Dis 2008, 47(1):63-65.
111. HPA Clostridium difficile Ribotyping Network (CDRN) for England and Northern Ireland 2009/2010 report 2011, [28 November 2011]; Available from:. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1296681523205.
112. Pepin J., Valiquette L., Gagnon S., Routhier S., Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007, 102(12):2781-2788.
113. Cozart J.C., Kalangi S.S., Clench M.H., Taylor D.R., Borucki M.J., Pollard R.B., et al. Clostridium difficile diarrhea in patients with AIDS versus non-AIDS controls. Methods of treatment and clinical response to treatment. J Clin Gastroenterol 1993, 16(3):192-194.
114. Barbut F., Depitre C., Delmee M., Corthier G., Petit J.C. Comparison of enterotoxin production, cytotoxin production, serogrouping, and antimicrobial susceptibilities of Clostridium difficile strains isolated from AIDS and human immunodeficiency virus-negative patients. J Clin Microbiol 1993, 31(3):740-742.
115. Pelaez T., Alcala L., Alonso R., Rodriguez-Creixems M., Garcia-Lechuz J.M., Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002, 46(6):1647-1650.
116. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009, 58(6):403-410.
117. Alonso R., Gros S., Pelaez T., Garcia-de-Viedma D., Rodriguez-Creixems M., Bouza E. Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea. J Hosp Infect 2001, 48(2):86-92.
118. van Kraaij M.G., Dekker A.W., Verdonck L.F., van Loon A.M., Vinje J., Koopmans M.P., et al. Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant 2000, 26(3):299-303.
119. Nusair A., Jourdan D., Medcalf S., Marion N., Iwen P.C., Fey P.D., et al. Infection control experience in a cooperative care center for transplant patients. Infect Control Hosp Epidemiol 2008, 29(5):424-429.
120. Cox G.J., Matsui S.M., Lo R.S., Hinds M., Bowden R.A., Hackman R.C., et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994, 107(5):1398-1407.
121. Vigil K., Sheppard T., Adachi J., del Busto R. High incidence of Clostridium difficile-associated diarrhea (CDAD) in hematopoietic stem cell transplant (HSCT) patients during 2005. Int J Infect Dis 2006, 10:S30-S31. [Meeting Abstract].
122. Chopra T., Chandrasekar P., Salimnia H., Heilbrun L.K., Smith D., Alangaden G.J. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 2011, 25(1):E82-E87.
123. Ahmad S., Ali M., Guddati A., Kumar N., Kumar G. Clostridium difficile associated diarrhea is a predictor of mortality in nationwide hospitalized bone marrow transplant patients. Gastroenterology 2011, 140(5):S350-S355. [Meeting Abstract].
124. Tomblyn M., Gordon L., Singhal S., Tallman M., Williams S., Winter J., et al. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant 2002, 30(8):517-519.
125. Yuen K.Y., Woo P.C., Liang R.H., Chiu E.K., Chen F.F., Wong S.S., et al. Clinical significance of alimentary tract microbes in bone marrow transplant recipients. Diagn Microbiol Infect Dis 1998, 30(2):75-81.
126. Dettenkofer M., Ebner W., Bertz H., Babikir R., Finke J., Frank U., et al. Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant 2003, 31(9):795-801.
127. Chakrabarti S., Lees A., Jones S.G., Milligan D.W. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant 2000, 26(8):871-876.
128. Dubberke E.R., Reske K.A., Srivastava A., Sadhu J., Gatti R., Young R.M., et al. Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 2010, 24(2):192-198.
129. Terada Y., Onishi Y., Kim S., Kami M., Mori S., Heike Y., et al. Clinical significance of positive Clostridium difficile (CD) toxin in the stool of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2004, 104(11):353B-B. [Meeting Abstract].
130. Arango J.I., Restrepo A., Schneider D.L., Callander N.S., Ochoa-Bayona J.L., Restrepo M.I., et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006, 37(5):517-521.
131. Harter C., Schulze B., Goldschmidt H., Benner A., Geiss H.K., Hoppe-Tichy T., et al. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 2006, 37(4):373-379.
132. Miller A.N., Glode A., Hogan K.R., Schaub C., Kramer C., Stuart R.K., et al. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010.
133. Bilgrami S., Feingold J.M., Dorsky D., Edwards R.L., Bona R.D., Khan A.M., et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999, 23(10):1039-1042.
134. Lew M.A., Kehoe K., Ritz J., Antman K.H., Nadler L., Kalish L.A., et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995, 13(1):239-250.
135. Leger C.S., Bredeson C., Kearns B., Bence-Bruckler I., Atkins H., Huebsch L. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000, 6(2A):204-210.
136. Burt R.K., Loh Y., Cohen B., Stefoski D., Balabanov R., Katsamakis G., et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009, 8(3):244-253.
137. Avery R., Pohlman B., Adal K., Bolwell B., Goldman M., Kalaycio M., et al. High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients. Bone Marrow Transplant 2000, 25(1):67-69.
138. Barton T., Collis T., Stadtmauer E., Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001, 32(3):391-395.
139. Jillella A.P., Ustun C., Robach E., Sertkaya D., DiPiro C., Kallab A.M., et al. Infectious complications in patients receiving mobilization chemotherapy for autologous peripheral blood stem cell collection. J Hematother Stem Cell Res 2003, 12(2):155-160.
140. Therriault B.L., Wilson J.W., Barreto J.N., Estes L.L. Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. Mayo Clin Proc 2010, 85(8):711-718.
141. Leung S., Metzger B.S., Currie B.P. Incidence of Clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol 2010, 31(3):313-315.
142. Chopra T., Alangaden G., Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti-Infective Ther 2010, 8(10):1113-1119. [Review].
143. Dubberke E.R., Sadhu J., Gatti R., Reske K.A., DiPersio J.F., Devine S.M., et al. Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol 2007, 28(2):208-211.
144. Poutanen S.M., Simor A.E. Clostridium difficile-associated diarrhea in adults. CMAJ 2004, 171(1):51-58.
145. Turgeon D.K., Novicki T.J., Quick J., Carlson L., Miller P., Ulness B., et al. Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. J Clin Microbiol 2003, 41(2):667-670.
146. Altclas J., Requejo A., Jaimovich G., Milovic V., Feldman L. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2002, 34(5):723.
147. Stelzmueller I., Goegele H., Biebl M., Wiesmayr S., Berger N., Tabarelli W., et al. Clostridium difficile colitis in solid organ transplantation-a single-center experience. Dig Dis Sci 2007, 52(11):3231-3236.
148. Theunissen C., Knoop C., Nonhoff C., Byl B., Claus M., Liesnard C., et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl Infect Dis 2008, 10(4):240-244.
149. Gunderson C.C., Gupta M.R., Lopez F., Lombard G.A., LaPlace S.G., Taylor D.E., et al. Clostridium difficile colitis in lung transplantation. Transpl Infect Dis 2008, 10(4):245-251.
150. Wong N.A., Bathgate A.J., Bellamy C.O. Colorectal disease in liver allograft recipients - a clinicopathological study with follow-up. Eur J Gastroenterol Hepatol 2002, 14(3):231-236.
151. Hashimoto M., Sugawara Y., Tamura S., Kaneko J., Matsui Y., Togashi J., et al. Clostridium difficile-associated diarrhea after living donor liver transplantation. World J Gastroenterol 2007, 13(14):2072-2076.
152. Albright J.B., Bonatti H., Mendez J., Kramer D., Stauffer J., Hinder R., et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int 2007, 20(10):856-866.
153. Vahabzadeh B., Ringold D., Reske K., Dubberke E., Lisker-Melman M. Clostridium difficile infection (cdi) rates are higher in patients with liver disease and liver transplant recipients than patients without liver disease. Hepatology 2008, 48(4):795A-796A. [Meeting Abstract].
154. Ali M., Kumar N., Patel J., Ahmad S., Kumar G., Saeian K. Clostridium difficile infection in hospitalized liver transplant patients. Gastroenterology 2011, 140(5):S962-S966. [Meeting Abstract].
155. Wistrom J., Norrby S.R., Myhre E.B., Eriksson S., Granstrom G., Lagergren L., et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001, 47(1):43-50.
156. Samore M.H., DeGirolami P.C., Tlucko A., Lichtenberg D.A., Melvin Z.A., Karchmer A.W. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994, 18(2):181-187.
157. Yousuf K., Saklayen M.G., Markert R.J., Barde C.J., Gopalswamy N. Clostridium difficile-associated diarrhea and chronic renal insufficiency. South Med J 2002, 95(7):681-683.
158. Cunney R.J., Magee C., McNamara E., Smyth E.G., Walshe J. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant 1998, 13(11):2842-2846.
159. Leung A.C., Orange G., McLay A., Henderson I.S. Clostridium difficile-associated colitis in uremic patients. Clin Nephrol 1985, 24(5):242-248.
160. Mitu-Pretorian O.M., Forgacs B., Qumruddin A., Tavakoli A., Augustine T., Pararajasingam R. Outcomes of patients who develop symptomatic Clostridium difficile infection after solid organ transplantation. Transplant Proc 2010, 42(7):2631-2633.
161. Zerey M., Paton B.L., Lincourt A.E., Gersin K.S., Kercher K.W., Heniford B.T. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt) 2007, 8(6):557-566.
162. Mori T., Kato J. Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int J Hematol 2010, 91(4):588-595.
163. Feuchtinger T., Lang P., Handgretinger R. Adenovirus infection after allogeneic stem cell transplantation. Leuk Lymphoma 2007, 48(2):244-255.
164. Veroux M., Puzzo L., Corona D., Buffone A., Tallarita T., Murabito P., et al. Cytomegalovirus and Clostridium difficile ischemic colitis in a renal transplant recipient: a lethal complication of anti-rejection therapy?. Urol Int 2007, 79(2):177-179. discussion 80.
165. Dahman M., Krell R., Brayman K., Sawyer R.G., Cathro H.P., Hagspiel K.D., et al. Simultaneous Clostridium difficile-associated colitis and late-onset intestinal cytomegalovirus disease in a renal transplant recipient. Ann Transplant 2010, 15(4):72-76.
166. Yates B., Murphy D.M., Fisher A.J., Gould F.K., Lordan J.L., Dark J.H., et al. Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation. Thorax 2007, 62(6):554-556.
167. Yolken R.H., Bishop C.A., Townsend T.R., Bolyard E.A., Bartlett J., Santos G.W., et al. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med 1982, 306(17):1010-1012.
168. Kang G., Srivastava A., Pulimood A., Dennison D., Chandy M. Etiology of diarrhea in patients undergoing allogeneic bone marrow transplantation in south India. Transplantation 2002, 73(8):1247-1251. [Article].